Aclaris Therapeutics Inc. (ACRS) Upgraded to Hold by Zacks Investment Research
Aclaris Therapeutics Inc. (NASDAQ:ACRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
A number of other equities analysts have also weighed in on the company. JMP Securities assumed coverage on Aclaris Therapeutics in a research note on Friday, September 30th. They issued an “outperform” rating and a $34.00 target price on the stock. Jefferies Group upped their target price on Aclaris Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, September 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $31.80.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/aclaris-therapeutics-inc-acrs-upgraded-to-hold-by-zacks-investment-research.html
Aclaris Therapeutics (NASDAQ:ACRS) traded up 1.9757% during trading on Tuesday, hitting $22.6896. The company had a trading volume of 58,230 shares. Aclaris Therapeutics has a 1-year low of $12.99 and a 1-year high of $33.88. The stock’s market capitalization is $485.90 million. The company’s 50 day moving average price is $23.71 and its 200-day moving average price is $20.82.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.01. On average, analysts expect that Aclaris Therapeutics will post ($2.60) EPS for the current year.
In other news, major shareholder Ra Capital Management, Llc sold 525,550 shares of the stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $24.19, for a total transaction of $12,713,054.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kamil Ali-Jackson sold 3,738 shares of the stock in a transaction dated Friday, August 26th. The shares were sold at an average price of $20.35, for a total value of $76,068.30. Following the transaction, the insider now owns 20,289 shares in the company, valued at $412,881.15. The disclosure for this sale can be found here. Insiders own 46.40% of the company’s stock.
Several institutional investors have recently made changes to their positions in ACRS. Nationwide Fund Advisors raised its position in shares of Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock valued at $106,000 after buying an additional 1,838 shares during the period. Geduld E E boosted its stake in shares of Aclaris Therapeutics by 62.5% in the second quarter. Geduld E E now owns 17,500 shares of the company’s stock valued at $323,000 after buying an additional 6,729 shares in the last quarter. EAM Investors LLC bought a new stake in shares of Aclaris Therapeutics during the second quarter valued at $668,000. Emerald Acquisition Ltd. bought a new stake in shares of Aclaris Therapeutics during the second quarter valued at $500,000. Finally, Swiss National Bank bought a new stake in shares of Aclaris Therapeutics during the second quarter valued at $283,000. Hedge funds and other institutional investors own 71.39% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.